104145-95-1
Chemical Structure
Cefditoren
- CAS No.: 104145-95-1
- Formula:C19H18N6O5S3
- Molecular Weight:506.58
InChIKey: KMIPKYQIOVAHOP-YLGJWRNMSA-N
SMILES: OC(C1=C(/C=C\C2=C(N=CS2)C)CS[C@@]([C@@H]3NC(/C(C4=CSC(N)=N4)=N\OC)=O)([H])N1C3=O)=O
Biological Activity: Cefditoren is a broad-spectrum oral active cephalosporin that acts as a penicillin-binding protein (PBP) inhibitor. Cefditoren binds to specific PBPs in Gram-positive and Gram-negative bacteria, thereby inhibiting cell wall synthesis. Cefditoren also reduces serum levels of the inflammatory biomarkers IL-6 and KL-6. Cefditoren can be used in research related to acute exacerbation of chronic bronchitis, pharyngitis-tonsillitis, uncomplicated skin and skin structure infections, respiratory tract infections, acute pyelonephritis, and enterococcal endocarditis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cefditoren | 98.14% | Cefditoren is a broad-spectrum oral active cephalosporin that acts as a penicillin-binding protein (PBP) inhibitor. Cefditoren binds to specific PBPs in Gram-positive and Gram-negative bacteria, thereby inhibiting cell wall synthesis. Cefditoren also reduces serum levels of the inflammatory biomarkers IL-6 and KL-6. Cefditoren can be used in research related to acute exacerbation of chronic bronchitis, pharyngitis-tonsillitis, uncomplicated skin and skin structure infections, respiratory tract infections, acute pyelonephritis, and enterococcal endocarditis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cefditoren-13C,d3 | Cefditoren-13C,d3 is the deuterium and 13C labeled Cefditoren. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cefditoren-d3 | Cefditoren-d3 is the deuterium labeled Cefditoren. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Jones RN, et al. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods. Diagn Microbiol Infect Dis. 2001 Sep-Oct;41(1-2):1-14. [Content Brief]
- [2]. Balbisi EA, et al. Cefditoren, a new aminothiazolyl cephalosporin. Pharmacotherapy. 2002;22(10):1278-1293. [Content Brief]
- [3]. Giuliano S, et al. Cefditoren: a clinical overview. New Microbiol. 2023;46(1):9-17. [Content Brief]
